News—
Why #KidneyCancer Rates Differ Globally.
bit.ly/3UHK32T

News—
#Glioma Approval Sets New Course in Pediatric Drug Development.
bit.ly/4ai0wRf

Did u know the AACR Journals has simultaneous publication opportunities? Here's a picture of first author Sumanta K. Pal (Sumanta K. Pal, MD, FASCO) presenting his article that published at #AACR24 .
aacrjournals.org/cancerdiscover…

Read Cancer Discovery's #ResearchWatch :
IGSF8 on Cancer Cells Suppresses NK Cell–Mediated Cytotoxicity, summarizing work by Xihao Hu, Xiaole Shirley Liu, Tengfei Xiao et al.
bit.ly/44Ks68g

New from the May issue of Cancer Discovery—
Jak2V617F Reversible Activation Shows Its Essential Requirement in #MyeloproliferativeNeoplasms , by Andrew Dunbar, Bobby Bowman, Ross Levine, Ross Levine Lab et al.
bit.ly/4bloo7U
Memorial Sloan Kettering Cancer Center #mpnsm

Did u know the AACR Journals has simultaneous publication opportunities? Here's a picture of first author Rona Yaeger presenting her article that published at #AACR24 .
aacrjournals.org/cancerdiscover…

Dennis Lo ⁦CUHK Medicine⁩ (and ⁦Cancer Discovery⁩ board member!) gave a fantastic talk about his lab’s seminal work identifying and characterizing DNA fragmentomics, which has already been clinically applied #liquidbiopsy

.Aadel Chaudhuri, MD PhD presented some hot-off-the-press data (coming out soon in Clinical Cancer Research!) showing the power of different aspects of cfDNA biology in distinguishing between MPNST and plexiform tumors as well as early detection/potentially alerting to imminent metastasis

.Pugh Lab described the amazing work leading to the development of an integrated cfDNA surveillance platform that detected cancer prior to standard clinical assays in patients with Li-Fraumeni syndrome: check out the related Cancer Discovery paper aacrjournals.org/cancerdiscover…

There have been several questions about the potential various sources of non-tumor cfDNA during this National Cancer Institute symposium on liquid biopsies: some potential sources described by @ et al aacrjournals.org/cancerdiscover…

.⁦Margaret Foti, PhD, MD (hc)⁩ starts off the Congressional briefing on the ⁦@AACR⁩ Cancer Disparities report by outlining the importance to characterize and understand the barriers to equitable cancer care: take a closer look for yourself here 👉🏻 cancerprogressreport.aacr.org/disparities/

And Cancer Discovery is so lucky to have Dr. Rob Winn on our Editorial Board!

Brian King FDA Tobacco: “what gets measured gets done”, i.e. it’s necessary to identify and chronicle cancer disparities

.Marcia Cruz-Correa, MD, PhD discusses the barriers facing clinicians as well as patients in accessing therapies for designing and running clinical trials: some progress is being made (see aacrjournals.org/cancerdiscover…)

(2/2) the 2024 report identifies the closing of the gap for certain groups but continues to exist overall, and so he issued a call to action

.Dr. Rob Winn summarizing the impact of the AACR cancer disparities report (which he skillfully helmed), the first of which was instrumental in identifying the gap in outcomes for different races/ethnicities/genders/LGBTQA+/geographic communities (1/2)

What if we could spot the warning signs of cancer earlier than ever? Ken Lau Lab’s new research explores foundational changes that may one day help us better tackle various cancers, potentially including #EGFR + #lungcancer 👉 medschool.vanderbilt.edu/basic-sciences… #HallmarksofPrecancer Cancer Discovery

So happy to share this paper investigating evolutionarily-conserved perivascular #meningioma stem cells and radiation resistance! Abrar Choudhury, MD, PhD Elizabeth Crouch, MD/PhD UCSF Neurosurgery UCSF Helen Diller Family Comprehensive Cancer Ctr @UCSF

Now online in Cancer Discovery: Perivascular NOTCH3+ Stem Cells Drive #Meningioma Tumorigenesis and Resistance to Radiotherapy - by Abrar Choudhury, MD, PhD, Martha Cady, RaleighLab, and colleagues doi.org/10.1158/2159-8… UC San Francisco

New from the May issue of Cancer Discovery—
#Sotorasib Is a pan-RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C cancers, by Doug Rubinson, Noritaka Tanaka, Andrew Aguirre, Ryan Corcoran et al.
bit.ly/4byHG9m
Dana-Farber Mass General Cancer Center #KRAS